Abstract
The effects of low-dose phenobarbitone on three indices of hepatic enzyme induction were studied. Eight healthy volunteers took phenobarbitone 7.5 mg daily for 4 weeks followed by 15 mg daily for 4 weeks; five subjects took 30 mg daily for a further 2 weeks. Phenobarbitone 15 mg daily produced a significant rise in antipyrine clearance (P less than 0.05). Phenobarbitone 30 mg daily produced a further rise, but probably because of the reduced numbers of subjects, this did not achieve significance (P = 0.06). Urinary 6-beta-hydroxycortisol and D-glucaric acid levels did not change significantly and remained within the range seen in subjects not taking enzyme-inducing drugs. We conclude that phenobarbitone 7.5 mg daily produces little (if any) enzyme induction whereas 15 mg, or more, may have the potential to produce drug interactions through enzyme induction.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Breckenridge A. Clinical implications of enzyme induction. Basic Life Sci. 1975;6:273–301. doi: 10.1007/978-1-4615-8954-9_9. [DOI] [PubMed] [Google Scholar]
- Breckenridge A., Orme M. L., Davies L., Thorgeirsson S. S., Davies D. S. Dose-dependent enzyme induction. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):514–520. doi: 10.1002/cpt1973144part1514. [DOI] [PubMed] [Google Scholar]
- Danhof M., Groot-van der Vis E., Breiner D. D. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology. 1979;18(4):210–223. doi: 10.1159/000137254. [DOI] [PubMed] [Google Scholar]
- Feely M., Price D., Cooke J. Phenobarbital in the monitoring of compliance. Ann Intern Med. 1984 Jul;101(1):138–139. doi: 10.7326/0003-4819-101-1-138_2. [DOI] [PubMed] [Google Scholar]
- Gill R., Lopes A. A., Moffat A. C. Analysis of barbiturates in blood by high-performance liquid chromatography. J Chromatogr. 1981 Nov 13;226(1):117–123. doi: 10.1016/s0378-4347(00)84212-7. [DOI] [PubMed] [Google Scholar]
- Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979 Mar 26;15(2):139–145. doi: 10.1007/BF00609878. [DOI] [PubMed] [Google Scholar]
- Park B. K. A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem. 1978 Oct;9(10):963–966. doi: 10.1016/0022-4731(78)90058-4. [DOI] [PubMed] [Google Scholar]
- Perucca E., Ruprah M., Richens A., Park B. K., Betteridge D. J., Hedges A. M. Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects. Br J Clin Pharmacol. 1981 Oct;12(4):592–596. doi: 10.1111/j.1365-2125.1981.tb01274.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simmons C. J., Davis M., Dordoni B., Williams R. Urinary D-glucaric acid assay by an improved enzymatic procedure. Clin Chim Acta. 1974 Feb 28;51(1):47–51. doi: 10.1016/0009-8981(74)90060-6. [DOI] [PubMed] [Google Scholar]
- Tavoloni N., Wittman R., Jones M. J., Berk P. D. Effect of low-dose phenobarbital on hepatic microsomal UDP-glucuronyl transferase activity. Biochem Pharmacol. 1983 Jul 15;32(14):2143–2147. doi: 10.1016/0006-2952(83)90219-8. [DOI] [PubMed] [Google Scholar]
- Vesell E. S., Page J. G. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest. 1969 Dec;48(12):2202–2209. doi: 10.1172/JCI106186. [DOI] [PMC free article] [PubMed] [Google Scholar]